Treatment of the Left Ventricular Thrombus with Integrated Traditional Chinese and Western Medicine: A Case Report

Qiuxiong Chen , Chuangpeng Li , Peizhong Liu , Yiting Lu , Rongyuan Yang , Qing Liu

›› 2022, Vol. 1 ›› Issue (1) : 32 -37.

PDF
›› 2022, Vol. 1 ›› Issue (1) :32 -37. DOI: 10.14218/FIM.2022.00037
Case Report
research-article
Treatment of the Left Ventricular Thrombus with Integrated Traditional Chinese and Western Medicine: A Case Report
Author information +
History +
PDF

Abstract

Left ventricular thrombus (LVT) is a common complication of coronary heart disease; thus, traditional Chinese medicine has become a therapeutic option. Here we report two LVT cases treated with Western medicine and traditional Chinese herbal medicine. After treatment, the thrombus became obviously smaller than before, and the clinical symptoms were also relieved. Furthermore, there was little relevant literature in this field, so we expect that this report could support the efficacy of traditional Chinese medicine in treating LVT.

Keywords

Left ventricular thrombus / Integrated traditional Chinese and Western medicine / Complementary medicine / Decoction

Cite this article

Download citation ▾
Qiuxiong Chen, Chuangpeng Li, Peizhong Liu, Yiting Lu, Rongyuan Yang, Qing Liu. Treatment of the Left Ventricular Thrombus with Integrated Traditional Chinese and Western Medicine: A Case Report. , 2022, 1(1): 32-37 DOI:10.14218/FIM.2022.00037

登录浏览全文

4963

注册一个新账户 忘记密码

Acknowledgments

None.

Funding

This study was supported by the National Natural Science Foundation of China (No. 8227427 to QL), Guangdong Medical Science and Technology Research Fund Project (No. B2020155 to QL), Guangdong Provincial Bureau of Traditional Chinese Medicine Fund Project (No. 20221360 to QL), Zhuhai Medical Science and Technology Research Fund Project (No. ZH24013310210002PWC to QL), Special Funding for TCM Science and Technology Research of the Guangdong Provincial Hospital of Chinese Medicine (No. YN2020QN10 to QL), and Municipal School (College) Joint Funding Project of the Guangzhou Science and Technology Bureau (No. SL2023A03J00081 to QL).

Conflict of interest

No competing financial interests exist.

Author contributions

The study was designed by QL. The manuscript writing was performed by YL, CL, PL, and QL. The manuscript was revised by QC and RY, and finalized by QL. All authors read and revised the manuscript critically.

Ethical statement

The patients consented to anonymous publication of their data, which was gratefully acknowledged by the authors. The ethical approval was granted by the Ethics Committee of GDHCM.

References

[1]

Habash F, Vallurupalli S. Challenges in management of left ventricu-lar thrombus. Ther Adv Cardiovasc Dis 2017; 11(8):203-213. doi: 10.1177/1753944717711139,PMID:28589748.

[2]

Lee JM, Park JJ, Jung HW, Cho YS, Oh IY, Yoon CH, et al. Left ventricu-lar thrombus and subsequent thromboembolism, comparison of an-ticoagulation, surgical removal, and antiplatelet agents. J Atheroscler Thromb 2013; 20(1):73-93. doi:10.5551/jat.13540,PMID:22986555.

[3]

Shacham Y, Leshem-Rubinow E, Ben Assa E, Rogowski O, Topilsky Y, Roth A, et al. Frequency and correlates of early left ventricular thrombus formation following anterior wall acute myocardial infarc-tion treated with primary percutaneous coronary intervention. Am J Cardiol 2013; 111(5):667-670. doi:10.1016/j.amjcard.2012.11.016,PMID:23261006.

[4]

Gianstefani S, Douiri A, Delithanasis I, Rogers T, Sen A, Kalra S, et al. Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention. Am J Cardiol 2014; 113(7):1111-1116. doi:10.1016/j.amjcard.2013.12.015,PMID:24485697.

[5]

Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation af-ter acute myocardial infarction. Heart 2012; 98(23):1743-1749. doi:10.1136/heartjnl-2012-301962,PMID:23151669.

[6]

Maniwa N, Fujino M, Nakai M, Nishimura K, Miyamoto Y, Kataoka Y, et al. Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction. Eur Heart J 2018; 39(3):201-208. doi:10.1093/eurheartj/ehx551,PMID:29029233.

[7]

Harem CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32(23):2999-3054. doi:10.1093/eurheartj/ehr236,PMID:21873419.

[8]

Makrides CA. Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy. BMJ Case Rep 2016;2016:bcr2016217843. doi:10.1136/bcr-2016-217843,PMID:27797850.

[9]

Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohn-loser SH, et al. Uninterrupted Dabigatran versus Warfarin for Abla-tion in Atrial Fibrillation. N Engl J Med 2017; 376(17):1627-1636. doi:10.1056/NEJMoa1701005,PMID:28317415.

[10]

Li R, Zhao L, Wu N, Wang R, Cao X, Qiu X, et al. Proteomic analy-sis allows for identifying targets of Yinchenwuling Powder in hyper-lipidemic rats. J Ethnopharmacol 2016; 185:60-67. doi:10.1016/j.jep.2016.03.029, PMID:26976764.

[11]

Wang DS, Tang FQ, Xiao CJ, Chen FP, Yuan ZK, Huang XP, et al. Ef-fect and Mechanism of Yinchen Wuling Powder on Atherosclerosis Rats. Journal of Traditional Chinese Medicine 2008; 49(1):67-69. doi:10.3321/j.issn:1001-1668.2008.01.029.

[12]

Liu M, Zhao S. WuLing San in Treating 60 Cases of Chronic Heart Fail-ure. Western Journal of Traditional Chinese Medicine 2017; 30(2):74-75. doi:10.3969/j.issn.1004-6852.2017.02.026.

[13]

Ning R, Zhi L. Revised Wuling Powder Treat Chronic Heart Failure. Journal of Zhejiang Chinese Medical University 2012; 36(2):143-144. doi:10.3969/j.issn.1005-5509.2012.02.010.

[14]

Lin S, Liang BL, Chen L. Modified Zhenwu Decoction in Treating 50 Cases of Chronic Heart Failure. The Journal of Practical Medicine 2016; 32(1):140-142. doi:10.3969/j.issn.1006-5725.2016.01.045.

[15]

Zhang GP, Miao YC. Observation on The Therapeutic Effect of Zhenwu Decoction Combined with Conventional Western Medicine of Con-gestive Heart Failure. Shaanxi Journal of Traditional Chinese Medi-cine 2017; 38(7):861-862.

[16]

You GH. Protective effects of Jiawei Zhenwu decoction on rats with heart failure induced by adriamycin and its mechanism. Chinese Journal of Biochemical Pharmaceutics 2015; 11:33-36.

[17]

Ju J, Du WX. Pharmacodynamic material basis and mechanism on warming Yang to promote diuresis of Zhen-Wu decoction. Ji-lin Journal of Traditional Chinese Medicine 2016; 36(7):719-723. doi:10.13463/j.cnki.jlzyy.2016.07.021.

PDF

0

Accesses

0

Citation

Detail

Sections
Recommended

/